Aptose Biosciences Inc (APS)

3.46
+0.03(+0.87%)
  • Volume:
    400
  • Bid/Ask:
    3.45/3.47
  • Day's Range:
    3.40 - 3.46
  • Type:Equity
  • Market:Canada
  • ISIN:CA03835T2002
  • CUSIP:03835T200

APS Overview

Prev. Close
3.43
Day's Range
3.4-3.46
Revenue
-
Open
3.41
52 wk Range
3.05-9.29
EPS
-0.83
Volume
400
Market Cap
310.43M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,003
P/E Ratio
-
Beta
1.24
1-Year Change
-55.47%
Shares Outstanding
88,948,744
Next Earnings Date
Nov 16, 2021
What is your sentiment on Aptose Biosciences Inc?
or
Market is currently closed. Voting is open during market hours.

Aptose Biosciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralNeutralSellStrong Sell
Technical IndicatorsBuyBuyStrong BuyStrong SellStrong Sell
SummaryNeutralNeutralBuyStrong SellStrong Sell

Aptose Biosciences Inc Company Profile

Aptose Biosciences Inc Company Profile

Sector
Services
Employees
39
Market
Canada

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Read More
  • Any thoughts on this?
    0
    • 2021.06.14. Bought again @ 3.81 after the dive.
      0
      • 2021.06.08. Bought 3.80 and sold 6.80 in March 2021
        0
        • target at about 11.40$
          1
          • 100% BUY! Check it out!
            1
            • U wouldve made 5.78% on your money! 😃
              1
          • Encouraging newsChairman, President and Chief Executive Officer. “We are encouraged by the continued increase in plasma exposure, and we hope the current and future dose levels will deliver formal responses to these deeply relapsed or refractory CLL patients. In AML, we are pleased by the observation of an anti-leukemic blast reduction from 93% to 10% in one of our first patients who was heavily pretreated with several consecutive FLT3 inhibitors. For APTO-253, we continue to escalate the dose and observe MYC repression, suggesting future potential for broad anti-cancer activity. We are pleased by such indicators of activity from both CG-806 and APTO-253, and we look forward to providing further updates in the first half of 2021 and at the Annual EHA Meeting 2021.”
            2
            • APTO is a LT Stock, I see good things ahead as they get positive results from their studies..I have a good feeling about it, loaded up for LT at this price range
              1
              • I got in at 3.98, lets see how will it go
                1
                • Is time to buy?
                  0
                  • wait
                    1
                  • if you are interstates
                    0
                • BUY BUY BUY
                  0
                  • Hello? Anybody out there? I bought this at $1.00 after it was announced they were going to stop working on one drug and switching focus to another which brought price way down.
                    3
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.